Target
SPP1 / Osteopontin
Synonyms
SPP1 | BSPI | BNSP | Bone sialoprotein 1 | ETA-1 | Nephropontin | OPN | Secreted phosphoprotein 1 | SPP-1 | SPP1/CALPHA1 fusion | Urinary stone protein | Uropontin | Osteopontin | Bone sialoprotein I
Modifications
Carrier-free
Conjugations
Unconjugated
Predicted Molecular Weight
The 290 amino acid recombinant protein has a predicted molecular mass of approximately 33 kD. The DTT-reduced and non-reduced protein migrates approximately 55 kD by SDS-PAGE. The predicted N-terminal amino acid is Ile.
Expression System
HEK 293 Cells
Purification
Greater than 95% by SDS-PAGE
Usage Summary
Stock solutions can also be prepared at 50 - 100 µg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2 - 1% BSA or HSA.
Bio-Activity
Human Osteopontin inhibits the production of IFN-? in human activated T cells in a dose-dependent manner. The ED50 for this effect is 0.2 – 2.0 ng/mL.
Endotoxin
Less than 1 EU/µg (determined by LAL method).
Presentation
0.22 µm filtered protein solution in PBS, pH 7.2
Storage
Store unopened at 2°C to 8°C for up to 1 month, at -20°C for up to 6 months, or at -70°C for up to 1 year. Store diluted at -20°C to -70°C. Avoid freeze/thaw cycles. For maximum results, quick spin vial prior to opening.
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This protein carries the LSBio 100% Guarantee.
LSBio Guarantee